Future experiments will examine the toxicity profile of the new PI3K inhibitor and will determine if prodrugs based on this compound would provide more potent inhibition of PI3K in prostate tumors that secrete PSA compared to currently used PI3K inhibitors. This evidence concerns the gene KLK3 and prostate neoplasm.